Contract Exceeding SGD $5 Million Strengthens Recurring Revenue and Diversifies IFM Client Portfolio

SINGAPORE, April 7, 2026 /PRNewswire/ — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group” or the “Company”), a global leader in on-demand workforce solutions and integrated facilities management (IFM), today announced that its IFM subsidiary, Hong Ye Group Pte. Ltd., has been awarded a contract for high-level cleaning services with a major state-owned transportation authority in Singapore, commencing April 1, 2026. The contract’s option to extend at the client’s discretion brings the potential total value to more than SGD $5 million, enhancing the stability and visibility of YY Group’s recurring service revenues.

This contract win represents a significant milestone in YY Group’s growth and sector diversification strategy, marking an expansion into Singapore’s public transportation infrastructure sector and underscoring the Company’s ability to meet the rigorous operational, safety, and compliance standards required by entities managing critical national infrastructure. It also further broadens the Company’s client and revenue base, adding public transportation to an existing IFM customer portfolio spanning hotels, shopping malls, hospitals, commercial office buildings, and financial institutions.

Mike Fu, Group Chief Executive Officer of YY Group, commented, “Securing this long-term contract with a major state-owned transportation authority is a powerful validation of YY Group’s service capabilities and opens a significant new growth vertical for our IFM business. This win reflects a return on the operational investments and strategic acquisitions we made in 2025, which have transformed our platform and positioned us to compete for larger, longer-duration contracts. The contract provides meaningful long-term revenue visibility and supports our broader strategy of building a diversified, recurring revenue base. As Singapore continues to invest in expanding and maintaining its world-class public infrastructure, we are well-equipped to deliver the required high standards of facility maintenance, reinforcing our leadership in Singapore’s IFM industry.”

Under this engagement, Hong Ye Group will deliver specialized high-level cleaning services across a comprehensive network of elevated and underground rail stations, as well as multiple train depots. The scope of work encompasses station infrastructure spanning several major rail lines and light rail systems operated by one of Singapore’s largest public transport operators. Hong Ye Group has already begun mobilizing dedicated teams, operational workflows, and workforce management technologies to ensure seamless service delivery from the contract’s commencement.

The addition of this contract further strengthens YY Group’s position at the forefront of Singapore’s high-potential IFM landscape. The Company will continue pursuing opportunities in both established and emerging market segments as part of its broader strategy to diversify and scale across sectors, deepen client relationships, and build long-term recurring revenue streams.

About YY Group Holding Limited

YY Group Holding Limited (Nasdaq: YYGH) is a Singapore-headquartered, AI-powered workforce solutions and integrated facility management (IFM) provider operating across Asia and beyond. The Company’s intelligent workforce solutions platform, YY Circle, helps clients across hospitality, food and beverage, retail, and other service sectors predict, plan and optimize workforce deployment. In YY Group’s IFM business, its 24IFM software platform and comprehensive IFM subsidiary portfolio support clients across hospitality, transportation, banking, retail and mixed-use facilities.

As both business lines scale, the Company is systematically embedding AI and automation capabilities to improve service quality, reduce deployment costs, and drive long-term margin expansion.

Listed on the Nasdaq Capital Market, YY Group is committed to platform innovation, measurable client outcomes, and long-term value creation.

For more information on the Company, please visit https://yygroupholding.com/.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the YY Group Holding Limited’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to, (i) growth of the hospitality market (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, and (vi) our future business development, results of operations and financial condition. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release, and YY Group Holding Limited undertakes no duty to update such information, except as required under applicable law.

Investor Contact
Jason Phua Zhi Yong, Chief Financial Officer
YY Group
enquiries@yygroupholding.com

GWACHEON, South Korea, April 7, 2026 /PRNewswire/ — Park Systems Corp., the world’s leading provider of atomic force microscopy (AFM) solutions, today announced the opening of its new global headquarters in Gwacheon city, South Korea. The new campus marks the culmination of three decades of growth and the beginning of a new phase of global expansion.

Park Systems’ New Global Headquarters

The Gwacheon campus reflects Park Systems’ evolution from a Stanford-born research venture into a global leader in nanometrology. Located in Gwacheon Knowledge & Information Town near Seoul, the campus spans 27,000 square meters across 15 above-ground floors and 5 basement levels.

At the core of the facility is a basement-level industrial cleanroom with capacity for up to 35 industrial-grade metrology systems, designed to support the precision requirements of semiconductor fabrication and advanced packaging applications.

Dedicated research and demonstration labs provide a hands-on environment where customers can perform live measurements across Park Systems’ nanometrology portfolio—including AFM, imaging spectroscopic ellipsometry, and digital holographic microscopy—with direct support from application and engineering teams. More than 26% of the company’s global workforce is dedicated to R&D, a focus the new campus is designed to support and expand.

“For thirty years, we have pushed the limits of nanoscale measurement,” said Dr. Sang-il Park, Founder and CEO of Park Systems. “This new headquarters marks the beginning of our next phase of innovation as we continue to advance the boundaries of nanometrology.”

The Gwacheon headquarters also reflects Park Systems’ commitment to its people. Employee facilities include a fitness center, on-site childcare, a golf simulator lounge, and a cafeteria offering complimentary meals—supporting a work environment designed for long-term productivity and innovation.

Park Systems achieved a compound annual growth rate (CAGR) of 26% from 2015 to 2025 and was recognized as the global AFM market leader by MarketsandMarkets in its 2024 report, marking three consecutive years in the top position.

The company has been named to Forbes Asia’s Best Under a Billion list in 2020, 2023, and 2025, and has expanded its portfolio through the acquisitions of Accurion GmbH and Lyncée Tec SA.

ABOUT PARK SYSTEMS
Park Systems is a global leader in nanometrology, providing advanced measurement solutions for research and industrial applications. With regional offices across the Americas, Europe, and Asia, the company supports customers in semiconductor manufacturing, materials science, and nanotechnology research.

Its technology portfolio includes atomic force microscopy (AFM), imaging spectroscopic ellipsometry, digital holographic microscopy, white light interferometry, and active vibration isolation systems.

Founded by Dr. Sang-il Park, a contributor to the invention of AFM at Stanford University, the company has grown through continuous innovation and strategic acquisitions—including Accurion GmbH and Lyncée Tec SA—to lead the global nanometrology industry. Learn more at www.parksystems.com

• A nationwide initiative is linking tourism, retail, and small businesses to turn local consumption into a coordinated economic stimulus

SEOUL, South Korea, April 7, 2026 /PRNewswire/ — Amid evolving global economic conditions, South Korea is exploring a distinctive approach to economic stimulus – one that goes beyond traditional fiscal or monetary measures, and instead focuses on mobilizing consumption.

At the center of this approach is the Donghaeng Festival (K-Shopping Festa or 동행축제 in Korean), a nationwide initiative led by Korea’s Ministry of SMEs and Startups, literally meaning a “shared journey” or collective participation. What began as a seasonal sales campaign has evolved into a nationwide mechanism designed to channel spending toward small businesses and local economies.

A Nationwide Consumption Framework

The April 2026 edition illustrates the scale of this effort. Over a 30-day period, the festival brings together more than 33,000 SMEs and micro businesses across approximately 200 distribution channels, while connecting consumption to more than 50 regional festivals nationwide.

Scale alone does not explain its significance.

The Donghaeng Festival operates as a coordinated system. Travel, cultural events, and retail promotions are not run in parallel – they are structurally linked. Visitors are drawn into regional areas through festivals and tourism programs, and that movement is then converted into local spending across traditional markets, neighborhood stores, and small business networks.

The result is a deliberate circulation of demand – redirecting consumption away from concentration in major urban centers toward a broader economic base.

Government as Market Catalyst

This level of coordination does not emerge organically. It is actively enabled by the government, which brings together central ministries, local authorities, and private-sector platforms into a single operational framework.

Rather than acting as a direct market participant, the state functions as a catalyst – aligning incentives, lowering participation barriers, and synchronizing fragmented actors. Discount schemes, digital vouchers, and partnerships with major retailers and financial institutions are designed to accelerate consumer spending while ensuring that it reaches smaller businesses.

In effect, policy is used not to replace the market, but to organize it.

Impact on Small Businesses

For small and micro enterprises, the effects are immediate.

Many operate with limited financial buffers, making short-term demand fluctuations critical. The festival creates concentrated periods of high visibility and purchasing activity, allowing businesses to generate revenue, improve cash flow, and stabilize operations within a relatively short timeframe.

This is particularly significant outside major metropolitan areas, where local businesses are more exposed to declines in foot traffic and consumer demand.

Measured Economic Effects

The economic impact is increasingly measurable.

In 2025, three rounds of the Donghaeng Festival generated substantial sales volumes:

• KRW 313.5 billion (USD 209 million) in March
• KRW 702.2 billion (USD 468 million) in May
• KRW 1.39 trillion (USD 927 million) in September

Notably, indirect sales – reflecting spillover effects into surrounding commercial areas – account for a significant share of total activity. This suggests that the festival’s impact extends beyond official sales channels, stimulating broader local economies.

Local Economies, Tangible Effects

At the regional level, the outcomes are more modest in scale but highly concentrated.

Previous editions drew tens of thousands of visitors to local events, including around 18,000 visitors to Jeju Island, one of Korea’s primary tourism destinations, and approximately 9,000 visitors to Gwangju, a major regional city in the southwest.

For participating businesses, sales generated through these regional programs ranged from KRW 708 million (USD 470,000) to KRW 2.017 billion (USD 1.34 million) per cycle.

Such figures may appear limited in aggregate terms, but they represent meaningful gains for small merchants and local producers – where incremental revenue can directly affect business continuity.

Expanding Market Access

Another defining feature is the integration of distribution channels.

Participating firms are able to access a wide range of platforms simultaneously – from e-commerce and live commerce to department stores, hypermarkets, and convenience retail networks. This reduces structural barriers that typically limit small businesses’ access to larger markets.

The result is not just increased sales, but expanded visibility.

Beyond Short-Term Stimulus: A Model for Consumption-Led Growth

The Donghaeng Festival also serves a broader function in revitalizing domestic consumption. By aligning retail promotions with tourism and cultural experiences, it encourages both Korean consumers and international visitors to participate in local spending across regions.

For domestic households, the festival lowers the threshold for consumption through coordinated discounts and incentives, creating timely opportunities to re-engage with everyday spending. For international visitors, it offers structured entry points into Korea’s local economies – connecting travel experiences with neighborhood markets, regional products, and small businesses.

In this way, the initiative reinforces consumption not as a one-off response, but as a more sustained pattern of spending – linking short-term demand activation with a more resilient domestic consumption base.

Beyond its immediate impact, the model also carries broader policy implications on how consumption can be effectively mobilized.

The Donghaeng Festival demonstrates how domestic demand can be activated in a targeted and inclusive way – by integrating tourism, culture, and retail into a unified system that engages both residents and visitors. Rather than treating consumption as a passive outcome, it is actively designed and guided toward sectors and regions where its impact is most needed.

This approach builds growth not through isolated interventions, but through coordinated participation at scale – where individual spending, whether by local consumers or international tourists, contributes to a broader economic effect.

In a period defined by uncertainty, it offers a practical proposition: that strengthening domestic consumption – supported by both local demand and visitor spending – can provide a more stable foundation for economic resilience.

Rather than relying solely on large-scale policy shifts, the Donghaeng Festival suggests that growth can also be built through coordinated, everyday spending – distributed across regions, sectors, and communities.

RIVERSIDE, Calif., April 7, 2026 /PRNewswire/ — PartnerOne, one of the fastest-growing software groups in the world, has appointed Michael Detwiler as the new Chief Executive Officer for Mortgage Cadence.

PartnerOne recently acquired Mortgage Cadence, a leading provider of cloud-based digital lending solutions.

Mike is the original CEO and co-founder of Mortgage Cadence, building it into a leader in the mortgage industry. He is a very well-respected leader and a visionary executive with over 30 years of experience in mortgage lending software. After having grown Mortgage Cadence from its first steps in [2002] to 2015, Mike is back to lead it into the next decades of growth and innovation. He brings a strong record of scaling organizations, driving investments, and aligning people and technology to deliver a culture of customer centric success.

“I couldn’t be more enthusiastic about leading Mortgage Cadence as part of PartnerOne,” said Detwiler. “Our customers can plan on continued innovation in the age of AI and more importantly their being central to everything we do every day.”

“We are delighted to welcome Mike as our Mortgage Cadence CEO,” said Suzanne Fortman, Vice President at PartnerOne. “He brings a proven record of high performance and exemplary customer service that aligns seamlessly with PartnerOne’s fast-paced culture and long-term investment strategy. Mike is committed to building upon the company’s strong foundation, empowering teams, and driving sustainable growth as we continue to accelerate our momentum within the PartnerOne portfolio.” 

About PartnerOne 

PartnerOne is one of the fastest growing enterprise software groups in the world, with a proven track record of acquiring and growing enterprise software companies. Over 2000 enterprises and government organizations rely on PartnerOne software, including 80% of the largest companies in the world. With an “Acquire. Invest. Grow.” philosophy, PartnerOne provides a “forever-home” for acquired businesses and helps them thrive with shared resources and sustained investment. For more information, visit www.partnerone.com

About Mortgage Cadence 
Mortgage Cadence delivers the industry’s most complete, modern, cloud-based digital lending platform designed to provide an exceptional user experience throughout the entire mortgage lending life cycle, across all channels and products. With leading borrower point-of-sale through closing collaboration tools, the end-to-end platform is both complete and configurable, offering an open architecture designed to meet the needs of today’s lenders. The platform enables lenders to work more efficiently, leveraging automation and workflow tools that deliver excellent borrower, sales, and operational user experience. For more information, visit www.mortgagecadence.com. 

TriNetX® will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase® technology for research and patient care innovation

CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, April 7, 2026 /PRNewswire/ — TriNetX, the world’s leading federated health data network, today announced that it has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and current TriNetX partner. The acquisition expands TriNetX’s genomics data management and analytics capabilities, supporting federated capture of multiomic data. This accelerates healthcare providers’ ability to integrate phenotypic and multiomic data for improved care delivery and clinical research and enhances the ability of TriNetX’s life science customers to perform large-data research in a cost-effective manner. 

Zetta’s flagship platform, XetaBase, is a multiomic capture and analytics platform designed for population‑scale genomic analysis. XetaBase is currently in use by leading healthcare provider organizations, life sciences companies, and research institutes.

TriNetX and Zetta have worked closely together since 2024 as part of TriNetX’s genomics data program. During this collaboration, the companies completed substantial technical feasibility work demonstrating secure, federated querying across genomic and phenotypic data to deliver high-integrity, analytically robust insights. This work establishes a strong foundation for further expansion.

“Through our partnership activities, led by our Chief Operating Officer Steve Kundrot and team, we have developed deep familiarity with Zetta’s leadership, technological prowess, and fit-for-purpose approach and have been consistently impressed with Zetta’s trusted healthcare provider relationships and robust analytics platform,” said Jeff Margolis, Executive Chairman of TriNetX. “Welcoming Zetta’s XetaBase platform into the TriNetX ecosystem represents an important milestone for our organization.”

Mr. Margolis continued, “This acquisition reflects our commitment to advancing multiomic-enabled research and supporting healthcare providers with a practical, localized approach to scaling their data infrastructures.”

Jeffrey Brown, PhD, TriNetX Chief Scientific Officer added, “Our purpose of driving better human health through data is clearly enhanced by adding the XetaBase technology, as we strongly believe the integration of different data types is essential to clinical and scientific progress.” 

“I am proud of what the Zetta team has built and excited to see XetaBase become part of the TriNetX array of data, software, and intelligence capabilities,” said Ignacio Medina Castello, Chief Executive Officer and Chief Technology Officer of Zetta Genomics. “From the beginning, our collaboration with TriNetX demonstrated that genomic and clinical data can be securely connected in a federated way at scale. Fully joining forces with TriNetX allows that work to move forward faster and to reach a broader global community of healthcare and research partners.”

About TriNetX, LLC

TriNetX is The Global Truth Engine for Better Human Health™, helping organizations understand what’s really happening in patient care. We connect health systems, researchers, and companies around the globe to real‑world patient data so they can make better‑informed decisions—based on reality, not assumptions.

Data is sourced directly from 11,000+ healthcare provider sites across more than 20 countries and kept within those institutions to protect accuracy, privacy, and trust. TriNetX combines this data with scientific expertise and technology to help customers ask better questions, interpret results, and move forward with confidence.

Learn more at trinetx.com or follow TriNetX on LinkedIn.

Media Contact
TriNetX
Karen Tunks
Email: Karen.Tunks@TriNetX.com

-Fixed–dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-life of up to 12 hours. These data support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for obesity. 

-ASC30_39 FDC demonstrated excellent compatibility between ASC30 and ASC39 when combined together, with room temperature stability and a small pill size.

-ASC30 is a Phase III-ready oral small molecule GLP-1R agonist that had a favorable gastrointestinal (GI) profile with half the rate of vomiting vs. orforglipron, when both drugs are dosed with weekly titration. 

-ASC39, an oral small molecule amylin-selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.

-Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC oral tablets is expected in the third quarter of 2026.

HONG KONG, April 7, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that it has selected ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30, once-daily oral small molecule GLP-1R agonist and ASC39, once-daily oral small molecule amylin-selective amylin receptor agonist, for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC oral tablets for the treatment of obesity in the third quarter of 2026.

ASC30_39 FDC tablets, dosed orally in dogs, demonstrated excellent oral bioavailability, high drug exposure and a long half-life of up to 12 hours. These key parameters of ASC30_39 FDC tablets are consistent with those observed in their respective monotherapies in a head-to-head dog study. Furthermore, ASC30_39 FDC tablets, developed utilizing Ascletis’ proprietary formulation technology, demonstrated a good compatibility between ASC30 and ASC39 with room temperature stability and a small pill size. The combination of the excellent pharmacokinetic profile of ASC30_39 FDC, the potential best- in-class efficacy and gastrointestinal (GI) tolerability of ASC30 and the first eloralintide-like small molecule amylin support ASC30_39 FDC tablets as a potential novel one-pill-once-daily therapy for the treatment of obesity.

ASC30 is a Phase III-ready oral small molecule GLP-1R agonist that had a favorable gastrointestinal (GI) profile with half the rate of vomiting vs. orforglipron, when both drugs are dosed with weekly titration in non-head-to-head studies (Press release).

As a clinical development candidate, ASC39 is a potent and amylin-selective oral small molecule amylin receptor agonist and demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.

“Selection of this fixed dose combination, which we believe is the first publicly announced co-formulation of an oral GLP-1 and an oral amylin, is an important step in the development of a new oral, potentially synergistic combination of ASC30 and ASC39 for the treatment of obesity,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “We believe this fixed dose combination, which combines the key features of high bioavailability, high drug exposure, a long half-life, and the convenience of a small pill, has the opportunity to improve patient outcomes for the treatment of obesity.”

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist, for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com